Asogun, D. A., Gunther, S., Akpede, G. O., Ihekweazu, C. & Zumla, A. Lassa fever: epidemiology, clinical features, diagnosis, management and prevention. Infect. Dis. Clin. North Am. 33, 933–951 (2019).
Garry, R. F. Lassa fever – the road ahead. Nat. Rev. Microbiol. 21, 87–96 (2023).
Frame, J. D., Baldwin, J. M. Jr., Gocke, D. J. & Troup, J. M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg. 19, 670–676 (1970).
Basinski, A. J. et al. Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa. PLoS Comput. Biol. 17, e1008811 (2021).
Sogoba, N. et al. Lassa virus seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerg. Infect. Dis. 22, 657–663 (2016).
Grant, D. S. et al. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: a cross-sectional, population-based study. PLoS Negl. Trop. Dis. 17, e0010938 (2023).
Gunther, S. & Lenz, O. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41, 339–390 (2004).
Grant, A. et al. Junin virus pathogenesis and virus replication. Viruses 4, 2317–2339 (2012).
Lendino, A., Castellanos, A. A., Pigott, D. M. & Han, B. A. A review of emerging health threats from zoonotic New World mammarenaviruses. BMC Microbiol. 24, 115 (2024).
Bonthius, D. J. Lymphocytic choriomeningitis virus: a prenatal and postnatal threat. Adv. Pediatr. 56, 75–86 (2009).
Charrel, R. N. et al. Acquired hydrocephalus caused by a variant lymphocytic choriomeningitis virus. Arch. Intern. Med. 166, 2044–2046 (2006).
Fischer, S. A. et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354, 2235–2249 (2006).
Kinori, M., Schwartzstein, H., Zeid, J. L., Kurup, S. P. & Mets, M. B. Congenital lymphocytic choriomeningitis virus-an underdiagnosed fetal teratogen. J. AAPOS 22, 79–81.e71 (2018).
Larsen, P. D., Chartrand, S. A., Tomashek, K. M., Hauser, L. G. & Ksiazek, T. G. Hydrocephalus complicating lymphocytic choriomeningitis virus infection. Pediatr. Infect. Dis. J. 12, 528–531 (1993).
Yu, J. T., Culican, S. M. & Tychsen, L. Aicardi-like chorioretinitis and maldevelopment of the corpus callosum in congenital lymphocytic choriomeningitis virus. J. AAPOS 10, 58–60 (2006).
Gass, J. T. et al. Discovery of a novel lymphocytic choriomeningitis virus strain associated with severe human disease in immunocompetent patient, New Mexico. Emerg. Microbes Infect. 14, 2542250 (2025).
Bausch, D. G., Hadi, C. M., Khan, S. H. & Lertora, J. J. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin. Infect. Dis. 51, 1435–1441 (2010).
Cheng, H. Y. et al. Lack of evidence for ribavirin treatment of Lassa fever in systematic review of published and unpublished studies(1). Emerg. Infect. Dis. 28, 1559–1568 (2022).
Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int. J. Infect. Dis. 87, 15–20 (2019).
Raabe, V. N. et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin. Infect. Dis. 65, 855–859 (2017).
Salam, A. P. et al. Ribavirin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLoS Negl. Trop. Dis. 16, e0010289 (2022).
Enria, D. A., Briggiler, A. M. & Sanchez, Z. Treatment of Argentine hemorrhagic fever. Antivir. Res. 78, 132–139 (2008).
Southern, P. J. et al. Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology 157, 145–155 (1987).
Riviere, Y. et al. The S RNA segment of lymphocytic choriomeningitis virus codes for the nucleoprotein and glycoproteins 1 and 2. J. Virol. 53, 966–968 (1985).
Pinschewer, D. D., Perez, M. & de la Torre, J. C. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J. Virol. 77, 3882–3887 (2003).
Lee, K. J., Novella, I. S., Teng, M. N., Oldstone, M. B. & de La Torre, J. C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 74, 3470–3477 (2000).
Salvato, M. S. & Shimomaye, E. M. The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology 173, 1–10 (1989).
Strecker, T. et al. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. J. Virol. 77, 10700–10705 (2003).
Perez, M., Craven, R. C. & de la Torre, J. C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. USA 100, 12978–12983 (2003).
Urata, S. & Yasuda, J. Molecular mechanism of arenavirus assembly and budding. Viruses 4, 2049–2079 (2012).
Garten, W. in Activation of Viruses by Host Proteases Ch. 9 (Böttcher-Friebertshäuser, E., Garten, W., Klenk, H-D). (Springer, 2018).
Pasquato, A., Cendron, L. & Kunz, S. in Activation of Viruses by Host Proteases Ch. 3 (Böttcher-Friebertshäuser, E., Garten, W., Klenk, H-D). (Springer, 2018).
Beyer, W. R., Popplau, D., Garten, W., von Laer, D. & Lenz, O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 77, 2866–2872 (2003).
Lenz, O., ter Meulen, J., Klenk, H. D., Seidah, N. G. & Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. USA 98, 12701–12705 (2001).
Kunz, S., Edelmann, K. H., de la Torre, J.-C., Gorney, R. & Oldstone, M. B. A. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314, 168–178 (2003).
Wright, K. E., Spiro, R. C., Burns, J. W. & Buchmeier, M. J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology 177, 175–183 (1990).
Rojek, J. M., Lee, A. M., Nguyen, N., Spiropoulou, C. F. & Kunz, S. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J. Virol. 82, 6045–6051 (2008).
Hastie, K. M. et al. Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nat. Struct. Mol. Biol. 23, 513–521 (2016).
Richardson, C. et al. The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. Virology 155, 508–523 (1986).
Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 95, 5762–5767 (1998).
Keelapang, P. et al. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 78, 2367–2381 (2004).
McCune, J. M. et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53, 55–67 (1988).
Follis, K. E., York, J. & Nunberg, J. H. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology 350, 358–369 (2006).
Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899–909 (2021).
Klenk, H. D., Rott, R., Orlich, M. & Blodorn, J. Activation of influenza A viruses by trypsin treatment. Virology 68, 426–439 (1975).
Urata, S. et al. Analysis of assembly and budding of Lujo virus. J. Virol. 90, 3257–3261 (2015).
Altamura, L. A. et al. Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J. Virol. 81, 6632–6642 (2007).
Rojek, J. M. et al. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 84, 573–584 (2010).
Matloubian, M., Kolhekar, S. R., Somasundaram, T. & Ahmed, R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67, 7340–7349 (1993).
Mueller, S. N. et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl. Acad. Sci. USA 104, 15430–15435 (2007).
Sevilla, N. et al. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192, 1249–1260 (2000).
Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M. & Oldstone, M. B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160, 521–540 (1984).
Borrow, P., Evans, C. F. & Oldstone, M. B. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 69, 1059–1070 (1995).
Matloubian, M., Somasundaram, T., Kolhekar, S. R., Selvakumar, R. & Ahmed, R. Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J. Exp. Med. 172, 1043–1048 (1990).
Salvato, M., Borrow, P., Shimomaye, E. & Oldstone, M. B. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 65, 1863–1869 (1991).
Traub, E. Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity. J. Exp. Med. 63, 847–861 (1936).
Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998).
Oldstone, M. B. A. et al. Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics. Proc. Natl. Acad. Sci. USA 115, E7814–e7823 (2018).
Schnell, F. J., Sundholm, S., Crumley, S., Iversen, P. L. & Mourich, D. V. Lymphocytic choriomeningitis virus infection in FVB mouse produces hemorrhagic disease. PLoS Pathog. 8, e1003073 (2012).
Sanchez, A. B. & de la Torre, J. C. Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology 350, 370–380 (2006).
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).
Brooks, D. G. et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12, 1301–1309 (2006).
Danyukova, T., Schöneck, K. & Pohl, S. Site-1 and site-2 proteases: a team of two in regulated proteolysis. Biochim. Biophys. Acta Mol. Cell Res. 1869, 119138 (2022).
Velho, R. V. et al. Site-1 protease and lysosomal homeostasis. Biochim. Biophys. Acta Mol. Cell Res. 1864, 2162–2168 (2017).
Ohnishi, Y. et al. A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1. J. Virol. 68, 4075–4079 (1994).
Chiron, M. F., Fryling, C. M. & FitzGerald, D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J. Biol. Chem. 272, 31707–31711 (1997).
Takahashi, S. et al. A second mutant allele of furin in the processing-incompetent cell line, LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. J. Biol. Chem. 270, 26565–26569 (1995).
Sullivan, B. M., Teijaro, J. R., de la Torre, J. C. & Oldstone, M. B. Early virus-host interactions dictate the course of a persistent infection. PLoS Pathog. 11, e1004588 (2015).
Ng, C. T. et al. Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17, 653–661 (2015).
Sheehan, K. C. et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).
Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).
Mody, C. H., Chen, G. H., Jackson, C., Curtis, J. L. & Toews, G. B. Depletion of murine CD8+ T cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans. J. Lab Clin. Med. 121, 765–773 (1993).
Mody, C. H., Chen, G.-H., Jackson, C., Curtis, J. L. & Toews, G. B. Un vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain ofCryptococcus neoformans. Mycopathologia 125, 7–17 (1994).
Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056–8063 (1994).
Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003).
Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007).
Mueller, S. N. & Ahmed, R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 106, 8623–8628 (2009).
Zhou, X., Ramachandran, S., Mann, M. & Popkin, D. L. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. Viruses 4, 2650–2669 (2012).
Sandu, I., Cerletti, D., Claassen, M. & Oxenius, A. Exhausted CD8(+) T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection. Nat. Commun. 11, 4454 (2020).
Utzschneider, D. T. et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J. Exp. Med. 213, 1819–1834 (2016).
Sandu, I. et al. Landscape of exhausted virus-specific CD8 T cells in chronic LCMV infection. Cell Rep. 32, 108078 (2020).
Wolfe, T. et al. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J. Immunol. 169, 4867–4872 (2002).
Kang, S. S. & McGavern, D. B. Lymphocytic choriomeningitis infection of the central nervous system. Front. Biosci. 13, 4529–4543 (2008).
Matullo, C. M., O’Regan, K. J., Hensley, H., Curtis, M. & Rall, G. F. Lymphocytic choriomeningitis virus-induced mortality in mice is triggered by edema and brain herniation. J. Virol. 84, 312–320 (2010).
Bergthaler, A. et al. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc. Natl. Acad. Sci. USA 107, 21641–21646 (2010).
Kober, D. L. et al. Identification of a degradation signal at the carboxy terminus of SREBP2: a new role for this domain in cholesterol homeostasis. Proc. Natl. Acad. Sci. USA 117, 28080–28091 (2020).
Smelt, S. C. et al. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J. Virol. 75, 448–457 (2001).
Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738–750 (2015).
Urata, S. et al. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 85, 795–803 (2011).
Pasquato, A. et al. Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 423, 14–22 (2012).
Raini, S. K. et al. The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection. Antivir. Res. 192, 105121 (2021).
Blanchet, M., Sureau, C., Guévin, C., Seidah, N. G. & Labonté, P. SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection. Antivir. Res. 115, 94–104 (2015).
Wang, T. B. et al. SREBP1 site 1 protease inhibitor PF-429242 suppresses renal cell carcinoma cell growth. Cell Death Dis. 12, 717 (2021).
Uchida, L. et al. Suppressive effects of the site 1 protease (S1P) inhibitor, PF-429242, on Dengue virus propagation. Viruses 8, 46 (2016).
Cai, Y. et al. A Lassa virus live-attenuated vaccine candidate based on rearrangement of the intergenic region. mBio https://doi.org/10.1128/mBio.00186-20 (2020).
Iwasaki, M., Cubitt, B., Sullivan, B. M. & de la Torre, J. C. The high degree of sequence plasticity of the arenavirus noncoding intergenic region (IGR) enables the use of a nonviral universal synthetic IGR to attenuate arenaviruses. J. Virol. 90, 3187–3197 (2016).
Iwasaki, M., Ngo, N., Cubitt, B., Teijaro, J. R. & de la Torre, J. C. General molecular strategy for development of arenavirus live-attenuated vaccines. J. Virol. 89, 12166–12177 (2015).
Cai, Y. et al. A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. mBio https://doi.org/10.1128/mBio.00039-20 (2020).
Cooper, C. L. et al. Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials. EBioMedicine 114, 105647 (2025).
Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).
Garbutt, M. et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78, 5458–5465 (2004).
Cross, R. W. et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 40, 111094 (2022).
Marzi, A., Feldmann, F., Geisbert, T. W., Feldmann, H. & Safronetz, D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg. Infect. Dis. 21, 305–307 (2015).
Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736 (2015).